International Clinical Trial: IMaging of cancer imMUNOtherapy targets with Positron Emission Tomography: Characterising PD-L1 with 89Zr- Durvalumab (MEDl4736) - Phase 1

Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (ACTRN12625000840482) titled 'IMaging of cancer imMUNOtherapy targets with Positron Emission Tomography: Characterising PD-L1 with 89Zr- Durvalumab (MEDl4736) - Phase 1' on Aug. 5.

Study Type: Interventional

Study Design: Purpose: Treatment Allocation: Non-randomised trial Masking: Open (masking not used)

Primary Sponsor: Peter MacCallum Cancer Centre

Condition: Non Small Cell Lung Cancer Non Small Cell Lung Cancer Cancer - Lung - Non small cell

Intervention: Consented participants with non-small cell lung carcinoma will be injected with the 89Zr-durvalumab (89Zr-durva) PET tracer prior to scanning. 100MBq of 89Zr-durva will be give...